Literature DB >> 2802856

Thymectomy for myasthenia gravis: recent observations and comparisons with past experience.

D G Mulder1, M Graves, C Herrmann.   

Abstract

To our previous report on the results of thymectomy for myasthenia gravis in 249 patients operated on between 1954 and 1981, we add a current review of 84 patients treated between 1982 and 1987. All patients underwent a median sternotomy, although this was performed after a bilateral submammary skin incision in most of the 57 female patients. There were no operative deaths, but one late death occurred at 5 months. During a mean followup of 3.6 years, 67 patients (80%) benefited from operation with remission achieved in 30 (36%) and improvement noted in 37 (44%). Acetylcholine receptor site antibody was present in 43 patients, of whom 19 (44%) achieved remission in contrast to 9 (27%) of the 33 patients without antibody. Hyperplasia of the excised thymus in 38 patients was associated with remission in 20 (53%) in contrast to remission in 7 (20%) of the 35 patients whose glands were "normal" or atrophic. The best prognosis was found in the 23 patients who had both receptor site antibody and thymic hyperplasia, as remission occurred in 15 of them (65%) in contrast to only 6 (27%) of the 22 patients who had neither factor. Remission rates (remissions per 1,000 patient-months of follow-up) for the present series (84 patients), the previous group (249 patients), and the overall group (333 patients) are 9.95, 6.13, and 6.62, respectively.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2802856     DOI: 10.1016/s0003-4975(10)66861-0

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  13 in total

1.  Autoimmune disease and the nervous system.

Authors:  L Steinman
Journal:  West J Med       Date:  1992-06

Review 2.  [Application of the da Vinci robotic system in thoracic surgery].

Authors:  M Ismail; M Swierzy; M Ulrich; J C Rückert
Journal:  Chirurg       Date:  2013-08       Impact factor: 0.955

Review 3.  Thymectomy for myasthenia gravis.

Authors:  J D Urschel; R P Grewal
Journal:  Postgrad Med J       Date:  1998-03       Impact factor: 2.401

4.  Surgical treatment of myasthenia gravis in two major Middle East teaching hospitals: factors influencing outcome.

Authors:  S A Hassantash; D G Ashbaugh; E D Verrier; R V Maier
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

5.  Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis.

Authors:  S Schönbeck; F Padberg; R Hohlfeld; H Wekerle
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

6.  Thymectomy in black children with juvenile myasthenia gravis.

Authors:  K Lakhoo; J D Fonseca; J Rodda; M R Davies
Journal:  Pediatr Surg Int       Date:  1997-02       Impact factor: 1.827

7.  Results of transcervical thymectomy for myasthenia gravis in 100 consecutive patients.

Authors:  R F Calhoun; J H Ritter; T J Guthrie; A Pestronk; B F Meyers; G A Patterson; M S Pohl; J D Cooper
Journal:  Ann Surg       Date:  1999-10       Impact factor: 12.969

8.  Long-term outcome and quality of life after open and thoracoscopic thymectomy for myasthenia gravis: analysis of 131 patients.

Authors:  Kai Bachmann; Doreen Burkhardt; Inken Schreiter; Jussuf Kaifi; Christoph Busch; Gunther Thayssen; Jakob R Izbicki; Tim Strate
Journal:  Surg Endosc       Date:  2008-02-23       Impact factor: 4.584

Review 9.  Autoimmune disease and the nervous system. Biochemical, molecular, and clinical update.

Authors:  J E Merrill; M C Graves; D G Mulder
Journal:  West J Med       Date:  1992-06

10.  Autoimmune Myasthenia Gravis: Recommendations for Treatment and Immunologic Modulation.

Authors:  Vern C Juel; Janice M Massey
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.